Supernus Pharmaceuticals (SUPN) Revenue (2011 - 2025)

Supernus Pharmaceuticals (SUPN) has 15 years of Revenue data on file, last reported at $211.6 million in Q4 2025.

• On a quarterly basis, Revenue rose 21.48% year-over-year to $211.6 million in Q4 2025; TTM through Dec 2025 was $719.0 million, a 8.63% increase from a year earlier, with the FY2025 full-year figure at $719.0 million, up 8.63% from the prior year.
• Revenue for Q4 2025 stood at $211.6 million, up from $192.1 million in the prior quarter.
• Over the last five years, Revenue for SUPN reached as high as $211.6 million in Q4 2025 and fell as low as $130.9 million in Q1 2021.
• Historically, Revenue has averaged $161.8 million across 5 years, with a median of $161.7 million in 2021.
• Across the five-year window, Revenue jumped 37.86% in 2021 and slipped 20.28% in 2023, its largest moves.
• Year by year, Revenue stood at $159.0 million in 2021, then gained by 5.2% to $167.3 million in 2022, then decreased by 1.8% to $164.3 million in 2023, then grew by 5.99% to $174.2 million in 2024, then climbed by 21.48% to $211.6 million in 2025.
• Per Business Quant data, the three most recent Revenue figures were $211.6 million in Q4 2025, $192.1 million in Q3 2025, and $165.5 million in Q2 2025.